Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: An overview and current perspectives
Authors
Keywords
-
Journal
METABOLISM-CLINICAL AND EXPERIMENTAL
Volume 134, Issue -, Pages 155264
Publisher
Elsevier BV
Online
2022-07-08
DOI
10.1016/j.metabol.2022.155264
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat
- (2022) Eric J. Lawitz et al. Clinical Gastroenterology and Hepatology
- Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption
- (2022) Renshuai Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases
- (2022) Ji-Won Park et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease
- (2022) Luigi Mirarchi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
- (2022) Naim Alkhouri et al. JOURNAL OF HEPATOLOGY
- Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial
- (2022) Stephen A Harrison et al. Lancet Gastroenterology & Hepatology
- NAFLD as a metabolic disease in humans: A literature review
- (2021) Bertrand Cariou et al. DIABETES OBESITY & METABOLISM
- Nonalcoholic fatty liver disease: another leap forward
- (2021) Manal F. Abdelmalek Nature Reviews Gastroenterology & Hepatology
- Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non‐alcoholic fatty liver disease
- (2021) Christina M. Sciarrillo et al. LIVER INTERNATIONAL
- Pharmacologic inhibition of Ketohexokinase prevents fructose-induced metabolic dysfunction
- (2021) Jemy A. Gutierrez et al. Molecular Metabolism
- Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
- (2021) Frank Tacke et al. Annals of Translational Medicine
- Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease
- (2021) Atsushi Nakajima et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Posttranslational Regulation of HMG CoA Reductase, the Rate-Limiting Enzyme in Synthesis of Cholesterol
- (2021) Marc M. Schumacher et al. Annual Review of Biochemistry
- Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life
- (2021) Zobair M. Younossi et al. Clinical Gastroenterology and Hepatology
- TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
- (2021) Rohit Loomba et al. GASTROENTEROLOGY
- Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study
- (2021) Takeshi Okanoue et al. HEPATOLOGY RESEARCH
- A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage
- (2021) Suling Huang et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
- (2021) Stephen A. Harrison et al. NATURE MEDICINE
- Apoptotic cell signals and heterogeneity in macrophage function: Fine-tuning for a healthy liver
- (2021) Imke Liebold et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Safety, Pharmacokinetics, Pharmacodynamics, and Formulation of Liver‐Distributed Farnesoid X‐Receptor Agonist TERN‐101 in Healthy Volunteers
- (2021) Yujin Wang et al. Clinical Pharmacology in Drug Development
- Structural insights into the mechanism of human NPC1L1-mediated cholesterol uptake
- (2021) Miaoqing Hu et al. Science Advances
- A new perspective on NAFLD: Focusing on lipid droplets
- (2021) Eleonora Scorletti et al. JOURNAL OF HEPATOLOGY
- Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
- (2021) V. Ratziu et al. NATURE MEDICINE
- ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
- (2021) Roberto A. Calle et al. NATURE MEDICINE
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- (2021) Sven M. Francque et al. NEW ENGLAND JOURNAL OF MEDICINE
- EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
- (2021) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis
- (2020) Cristy R.C. Verzijl et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
- (2020) Vlad Ratziu et al. HEPATOLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials
- (2020) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
- (2020) F. Anthony Romero et al. JOURNAL OF MEDICINAL CHEMISTRY
- Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis
- (2020) Petra Hirsova et al. Cell Death & Disease
- c-Mpl and TPO expression in the human central nervous system neurons inhibits neuronal apoptosis
- (2020) Liang Li et al. Aging-US
- Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
- (2020) Jean-François Dufour et al. GUT
- The L‐α‐lysophosphatidylinositol/GPR55 system induces the development of non‐alcoholic steatosis and steatohepatitis
- (2020) Marcos F. Fondevila et al. HEPATOLOGY
- Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
- (2020) Yoshio Sumida et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study
- (2020) Philip N. Newsome et al. JOURNAL OF HEPATOLOGY
- Evaluation of NAFLD and fibrosis in obese patients – a comparison of histological and clinical scoring systems
- (2020) Sophia Marie-Therese Schmitz et al. BMC GASTROENTEROLOGY
- Evolving role for pharmacotherapy in NAFLD/NASH
- (2020) Suzanna L. Attia et al. CTS-Clinical and Translational Science
- Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)
- (2020) Stefano Fiorucci et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
- (2020) Trenton T. Ross et al. Cellular and Molecular Gastroenterology and Hepatology
- Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers
- (2020) Stephen A. Harrison et al. Contemporary Clinical Trials
- Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis
- (2020) Shinji Takai et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pathophysiology of Type 2 Diabetes Mellitus
- (2020) Unai Galicia-Garcia et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose
- (2020) Kentaro Futatsugi et al. JOURNAL OF MEDICINAL CHEMISTRY
- FGF19 and FGF21: In NASH we trust
- (2020) Saswata Talukdar et al. Molecular Metabolism
- Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies
- (2020) Carmelo Luci et al. Frontiers in Endocrinology
- Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH
- (2020) Rohit Loomba et al. HEPATOLOGY
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis
- (2019) Jingjing Cai et al. HEPATOLOGY
- Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease
- (2019) Hsu-Wen Chao et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial
- (2019) Soraiya Ebrahimpour-Koujan et al. Trials
- A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH)
- (2019) Manca Povsic et al. ADVANCES IN THERAPY
- Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A Systematic Review and Meta‐Analysis
- (2019) Feng Zhou et al. HEPATOLOGY
- Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
- (2019) Fernando Bril et al. DIABETES CARE
- GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)
- (2019) Naim Alkhouri et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
- (2019) Juliette Mouries et al. JOURNAL OF HEPATOLOGY
- CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients
- (2019) Paul J. Pockros et al. LIVER INTERNATIONAL
- Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients
- (2019) Giada Sebastiani et al. AIDS
- Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis
- (2019) Neeta B. Amin et al. Science Translational Medicine
- Polyphenol Effects on Cholesterol Metabolism via Bile Acid Biosynthesis, CYP7A1: A Review
- (2019) Karen F. Chambers et al. Nutrients
- Diversification of host bile acids by members of the gut microbiota
- (2019) Jenessa A. Winston et al. Gut Microbes
- Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design
- (2019) Quentin M. Anstee et al. Contemporary Clinical Trials
- Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension
- (2019) Guadalupe Garcia-Tsao et al. JOURNAL OF HEPATOLOGY
- A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
- (2019) Joost Boeckmans et al. Cells
- Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial
- (2018) Marc R. Bomhof et al. EUROPEAN JOURNAL OF NUTRITION
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
- (2018) Samar H Ibrahim et al. GUT
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study
- (2018) Alina M. Allen et al. HEPATOLOGY
- Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers
- (2018) Eduardo Vilar-Gomez et al. JOURNAL OF HEPATOLOGY
- Determinants of fibrosis progression and regression in NASH
- (2018) Detlef Schuppan et al. JOURNAL OF HEPATOLOGY
- Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2018) Pratik Devasthale et al. JOURNAL OF MEDICINAL CHEMISTRY
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Triggering and resolution of inflammation in NASH
- (2018) Susanne Schuster et al. Nature Reviews Gastroenterology & Hepatology
- Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches
- (2018) Antonella Borrelli et al. Redox Biology
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
- (2018) Stephen A. Harrison et al. PLoS One
- Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence
- (2018) Arrigo Cicero et al. Nutrients
- Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
- (2018) Samer Al-Dury et al. Frontiers in Pharmacology
- Molecular pathways of nonalcoholic fatty liver disease development and progression
- (2018) Fernando Bessone et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
- (2018) Brian N. Finck DIABETES
- The role of the microbiome in NAFLD and NASH
- (2018) Aleksandra A Kolodziejczyk et al. EMBO Molecular Medicine
- Non-alcoholic fatty liver disease – A global public health perspective
- (2018) Zobair M. Younossi JOURNAL OF HEPATOLOGY
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study
- (2017) Nicholas Siebers et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal
- (2017) Naoki Ikenaga et al. GUT
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Current and future pharmacological therapies for NAFLD/NASH
- (2017) Yoshio Sumida et al. JOURNAL OF GASTROENTEROLOGY
- The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
- (2017) Monica D. Chow et al. MOLECULAR ASPECTS OF MEDICINE
- A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis
- (2017) Stuart McPherson et al. PLoS One
- Insights into Stearoyl-CoA Desaturase-1 Regulation of Systemic Metabolism
- (2017) Ahmed M. ALJohani et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
- (2016) E Lefebvre et al. CTS-Clinical and Translational Science
- Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
- (2016) Juan P. Arab et al. HEPATOLOGY
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
- (2016) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
- (2016) Elena Buzzetti et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH)
- (2016) Marina Nati et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- The Role of Cholesterol in the Pathogenesis of NASH
- (2016) George N. Ioannou TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease
- (2016) Hui-Jie Zhang et al. JAMA Internal Medicine
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study
- (2016) Jaimini Cegla ANNALS OF CLINICAL BIOCHEMISTRY
- Molecular Pathways: Fatty Acid Synthase
- (2015) S. F. Jones et al. CLINICAL CANCER RESEARCH
- The regulation of function, growth and survival of GLP-1-producing L-cells
- (2015) R. E. Kuhre et al. CLINICAL SCIENCE
- High-dose vitamin D supplementation and liver histology in NASH: Table 1
- (2015) Matthew T Kitson et al. GUT
- Vascular adhesion protein 1 in nonalcoholic steatohepatitis: A novel biomarker?
- (2015) Natalie J. Torok HEPATOLOGY
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Current efforts and trends in the treatment of NASH
- (2015) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial
- (2015) Curtis K. Argo et al. JOURNAL OF HEPATOLOGY
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis
- (2015) Margarita Pizarro et al. LIVER INTERNATIONAL
- Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders
- (2015) Stefano Fiorucci et al. TRENDS IN MOLECULAR MEDICINE
- Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial
- (2015) Steven C. Lin et al. Therapeutic Advances in Gastroenterology
- The Emerging Landscape of RORγt Biology
- (2014) Jacob S. Lee et al. IMMUNITY
- Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis
- (2014) Kazutoshi Yamada et al. LIVER INTERNATIONAL
- Thyroid Hormone Regulation of Metabolism
- (2014) Rashmi Mullur et al. PHYSIOLOGICAL REVIEWS
- Decoding cell death signals in liver inflammation
- (2013) Catherine Brenner et al. JOURNAL OF HEPATOLOGY
- Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia
- (2012) Nezam H. Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice
- (2012) T. Ishimoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
- (2011) Claudia O. Zein et al. HEPATOLOGY
- An apoptosis panel for nonalcoholic steatohepatitis diagnosis
- (2010) Tarek I. Abu-Rajab Tamimi et al. JOURNAL OF HEPATOLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Molecular mechanism for the regulation of human ACC2 through phosphorylation by AMPK
- (2009) Yong Soon Cho et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
- (2009) Vlad Ratziu et al. HEPATOLOGY
- Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis
- (2008) R. LOOMBA et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now